Checkpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial D…

A phase 1 trial of relatlimab plus nivolumab in recurrent glioblastoma reveals that checkpoint inhibitor failure in brain tumours stems not from drug mechanism but from trial design architecture; the trial's protocol innovations—parallel cohorts, systematic neurological monitoring, pre-specified imaging windows—establish a replicable template for detecting efficacy signals in immunosuppressive CNS environments. If you're running a CNS immunotherapy programme, the relatlimab trial just published the operational playbook that turns inconclusive phase 1 data into actionable phase 2 design—systematic neuro monitoring, parallel cohorts without placebo control, pre-specified safety stopping rules. Copy this protocol architecture and you stop wasting patients on underpowered trials.